Immune Checkpoint Inhibition in Metastatic Urothelial Cancer

European Urology

Volumn 72, Issue 4, 2017, Pages 477-481

  Powles, Tom ^a   Smith, Kate ^a   Stenzl, Arnulf ^b   Bedke, Jens ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; PEMBROLIZUMAB; PLATINUM; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; TUMOR MARKER;

EDITORIAL; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UROGENITAL TRACT CANCER; UROTHELIAL CANCER; ADJUVANT CHEMOTHERAPY; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG EFFECT; IMMUNOLOGY; METABOLISM; METASTASIS; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; TIME FACTOR; TREATMENT OUTCOME; URINARY TRACT TUMOR; UROTHELIUM;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 85017435680     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2017.03.047     Document Type: Editorial

References (16)

1. Oing, C., Rink, M., Oechsle, K., et al. Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond-a comprehensive review of the current literature. J Urol 195 (2016), 254–263.
2. Sternberg, C.N., de Mulder, P.H., Schornagel, J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol 19 (2001), 2638–2646.
3. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
4. Bellmunt, J., de Wit, R., Vaughn, D.J., et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376 (2017), 1015–1026.
5. Massard, C., Gordon, M.S., Sharma, S., et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34 (2016), 3119–3125.
6. Sharma, P., Callahan, M.K., Bono, P., et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17 (2016), 1590–1598.
7. Apolo, A.B., Infante, J.R., Hamid, O., et al. Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase Ib trial. J Clin Oncol, 34(Suppl 2), 2016, 367.
8. O'Donnell, P.H., Plimack, E.R., Bellmunt, J., et al. Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: results of a phase IB study. J Clin Oncol, 33(Suppl 7), 2015, 296.
9. Powles, T., Eder, J.P., Fine, G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
10. Scheel, A.H., Dietel, M., Heukamp, L.C., et al. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer: current state of the art and experiences of the first German harmonization study]. Pathologe 37 (2016), 557–567.
11. Sharma, P., Retz, M., Siefker-Radtke, A., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18 (2017), 312–322.
12. Balar, A.V., Galsky, M.D., Loriot, Y., et al. Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): primary analysis of IMvigor210 cohort 1. J Clin Oncol, 34(Suppl), 2016, LBA4500.
13. Balar, A.V., Bellmunt, J., O'Donnell, P.H., et al. Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE-052 study. Ann Oncol, 27(Suppl 6), 2016, vi578.
14. Balar, A.V., Castellano, D.E., O'Donnell, P.H., et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: results from the total KEYNOTE-052 study population. J Clin Oncol, 35(Suppl 6), 2017, 284.
15. Frampton, G.M., Fichtenholtz, A., Otto, G.A., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
16. Sharma, P., Callahan, M.K., Calvo, E., et al. Efficacy and safety of nivolumab plus ipilimumab in previously treated metastatic urothelial carcinoma. Presented at the 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016), National Harbor, MD, USA, 2016.